+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Researchers are studying ZE46-0134, an investigational oral drug, in adults with relapsed or refractory acute myeloid leukemia AML who have specific gene mutations in FLT3 or spliceosome genes. This Phase 1, open-label study aims to assess the drugs safety, how it moves and works in the body pharmacokinetics and pharmacodynamics, and its preliminary effectiveness. AML is a serious blood cancer with poor survival rates, and mutations in FLT3 are common and contribute to disease progression. The study is divided into two parts Part 1 focuses on dose escalation to find the maximum tolerated dose, enrolling small groups of patients with either FLT3 or spliceosome mutations to receive up to 24 cycles of daily oral ZE46-0134 capsules. Part 2 involves dose expansion, with up to 30 patients in each mutation group receiving doses determined from Part 1. If patients benefit after 24 cycles, continuing treatment may be considered. Participants will undergo regular assessments including laboratory tests, safety monitoring, and pharmacokinetic sampling during the treatment cycles. Researchers will track adverse events, blood test results, and leukemia response up to six treatment cycles and beyond. The main outcome measured is the rate of dose-limiting toxicities during treatment, helping to evaluate the drugs safety profile. The study is expected to continue until December 2027.

Age: 18Years +All GendersPhase 1
23 locations